Učitavanje...

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat

Epigenetic regulation of gene transcription by small molecule inhibitors of histone deacetylases (HDAC) is a novel cancer therapy. Vorinostat (Zolinza(™)) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Duvic, Madeleine, Vu, Jenny
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2007
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721288/
https://ncbi.nlm.nih.gov/pubmed/19707308
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!